COMMUNITY OUTREACH AND ENGAGEMENT (COE) MD Anderson exists to ??eliminate cancer in Texas, the nation, and the world.? It achieves this mission by operating in four integrated domains ? research, clinical care, education, and prevention/control. Based upon its state charter, state support, patient population, and its primary commitment to improving the health of Texans, the institution defines the state of Texas as its primary catchment area. The Community Outreach and Engagement (COE) component highlights the institution's key resources, relationships, and evidence- based actions taken in priority areas to reduce Texans' cancer burden and associated risk factors. The second most populous state in the country (28.3M residents), Texas is highly diverse and has the greatest number of uninsured residents in the nation. Catchment area priorities include: tobacco use, obesity, ultraviolet radiation, rising rates of hepatocellular cancer (HCC), delivery of HPV vaccination, and equitable delivery of screening services for cervical and colorectal (CRC) cancer. MD Anderson's capacity to advance the health of Texans is sustained through key investments in resources, such as implementation expertise to achieve population level impact through the Cancer Prevention & Control Platform (CPCP), and research infrastructure to advance community informed community based studies through the Center for Community-Engaged Translational Research (CCETR). By activating its network of diverse relationships, including those with educational systems, as well as community and faith-based organizations, MD Anderson amplifies its reach and impact beyond its walls, enabling MD Anderson's connection to and partnership with the community. MD Anderson views research and control actions as complementary activities that inform each other to perpetuate a virtuous cycle to address the needs of Texans. To address identified priorities, MD Anderson leads an array of initiatives dedicated to advancing research and community engagement as well as evidence-based actions to improve public policy, professional and public education (knowledge dissemination), and community-oriented service delivery beyond its direct delivery of patient care services. These efforts are stewarded through engagement of a broad group of CCSG Research Program members and staff working collaboratively across multiple offices, community-based organizations, and clinical partners.
The aims of the COE component are:
Aim 1 : To assess and monitor catchment area rates and trends as well as emerging evidence-based practices in order to identify cancer-related needs and opportunities to address them.
Aim 2 : To plan and prioritize research and control actions to commit MD Anderson's resources (infrastructure and faculty expertise) and relationships and engage communities and partners.
Aim 3 : To implement and evaluate evidence-based actions in policy, public and professional education, and services to increase the use and impact of interventions that reduce the burden of cancer and associated risk factors at the population level and improve outcomes in Texas and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997837
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Bose, Prithviraj; Nazha, Aziz; Komrokji, Rami S et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132:2100-2103
Loehrer, Andrew P; Chang, David C; Song, Zirui et al. (2018) Health Reform and Utilization of High-Volume Hospitals for Complex Cancer Operations. J Oncol Pract 14:e42-e50
Suidan, Rudy S; Sun, Charlotte C; Cantor, Scott B et al. (2018) Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132:52-58
Lehrer, Michael; Bhadra, Anindya; Aithala, Sathvik et al. (2018) High-dimensional regression analysis links magnetic resonance imaging features and protein expression and signaling pathway alterations in breast invasive carcinoma. Oncoscience 5:39-48
Ng, Sweet Ping; Koay, Eugene J (2018) Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Ann Pancreat Cancer 1:
Kantarjian, Hagop; Ravandi, Farhad; Short, Nicholas J et al. (2018) Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19:240-248
Herbrich, Shelley M; Kannan, Sankaranarayanan; Nolo, Riitta M et al. (2018) Characterization of TRKA signaling in acute myeloid leukemia. Oncotarget 9:30092-30105
Yamashita, Suguru; Brudvik, Kristoffer Watten; Kopetz, Scott E et al. (2018) Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Ann Surg 267:514-520
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Meric-Bernstam, Funda; Johnson, Amber; Ileana Dumbrava, Ecaterina E et al. (2018) Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res :

Showing the most recent 10 out of 12418 publications